Perineurial Invasion of the Facial Nerve: A Case Report with Extension from Cutaneous Squamous Cell Carcinoma

1981 ◽  
Vol 89 (5) ◽  
pp. 831-835 ◽  
Author(s):  
Melvin Strauss ◽  
Cynthia Cohen
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Facial Nerve ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Clinical Importance ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Current Evidence ◽  
Nerve Paresis ◽  
Unusual Occurrence

A case report is presented of an unusual occurrence of peripheral facial nerve paresis owing to isolated perineurial extension from a cutaneous squamous cell carcinoma. Current evidence dispels the previously held belief that perineural invasion and extension occurs in lymphatic spaces. The clinical importance of recognizing this route of spread by tumors of the head and neck is discussed.

Primary Cutaneous Squamous Cell Carcinoma of Thigh A Case Report and Review of Literature

2016 ◽  
Vol 02 (01) ◽  
Author(s):  
Vishwas D Pai ◽  
Sushma V Pai ◽  
Vidhya Manohar ◽  
Suvarna Ravindranath ◽  
Mahantesh K Math
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Review Of Literature

scholarly journals Case Report: Cutaneous Squamous Cell Carcinoma Arising From the Ulcer of the Lesions of Dupuytren’s Disease on the Palm

2021 ◽  
Vol 11 ◽  
Author(s):  
Qingmiao Sun ◽  
Bin Fu ◽  
Sheng Li ◽  
Hong Fang ◽  
Jianjun Qiao
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
English Literature ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Dupuytren’S Disease ◽  
Dupuytren's Disease ◽  
The Relationship

Dupuytren’s disease is a benign fibromatosis that mainly involves the fascia of the palm and digits. The relationship between Dupuytren’s disease and the evolution of cutaneous squamous cell carcinoma is still unclear. Here we report the case of a 52-year-old female with squamous cell carcinoma arising from the ulcer of the lesions of Dupuytren’s disease on the left palm. To our knowledge, this is the first reported case in the English literature of squamous cell carcinoma on the palm of someone with Dupuytren’s disease.

scholarly journals Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations

2021 ◽  
Vol 11 (S2) ◽  
pp. e2021170S
Author(s):  
Paolo Bossi ◽  
Luigi Lorini
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Current Evidence ◽  
Special Populations ◽  
Solid Organ

Cutaneous squamous cell carcinoma (cSCC) may develop in patients with dysregulated immune activation (pre-existing autoimmune diseases or immunosuppression due to hematopoietic/solid organ transplant recipients), patients with a compromised immune function (long-term immunosuppression), and patients carrying chronic viral infections, or those affected by lymphoproliferative diseases. It should be also considered that patients presenting with immunosuppression have a high incidence of cSCC (65–250-times higher than general population), highlighting the central role played by the immune system in the development of cSCC. All these cases must be considered as “special populations” for treatment with immune checkpoint inhibitors (ICIs), as the safety and activity of these drugs have not been studied on these specific cases, since these patients were excluded from clinical trials leading to approval of ICIs. It is therefore important to gain as much information as possible from the analysis of real-life data, to derive an indication to be adopted in everyday clinical setting.  Moreover, therapeutic alternatives other than ICIs are scarce, mainly consisting in chemotherapy and anti-EGFR agents, whose activity is lower than immunotherapy and whose toxicity (particularly with chemotherapy) are not sustainable by this frail population. Here, we describe the current evidence of treatment with ICIs in special populations and conclude that it is necessary to find a balance between treatment risks (toxicities) and benefits (efficacy), as well as engaging a multidisciplinary team of experts to thoroughly manage and treat these patients.

Sign in / Sign up

Export Citation Format

Share Document